Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first‐line treatment for advanced EGFR‐mutant non‐small cell lung cancer

BACKGROUND: Dual blockade of both EGFR and VEGFR pathways in EGFR‐mutant NSCLC have shown enhanced antitumor efficacy versus EGFR‐TKIs alone. Apatinib is an orally effective VEGFR‐2 tyrosine kinase inhibitor (TKI). This pilot study aims to evaluate the tolerability, pharmacokinetic profile, and anti...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Transl Med
Principais autores: Zhang, Zhonghan, Zhang, Yang, Luo, Fan, Ma, Yuxiang, Fang, Wenfeng, Zhan, Jing, Li, Su, Yang, Yunpeng, Zhao, Yuanyuan, Hong, Shaodong, Zhou, Ting, Zhang, Yaxiong, Zhao, Shen, Huang, Yan, Zhao, Hongyun, Zhang, Li
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7403827/
https://ncbi.nlm.nih.gov/pubmed/32508029
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ctm2.33
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados